Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer

Zhang, Xiaozhu; Zhao, Yi; Wang, Miao; Yap, Wee See; Chang, Alex Y.

doi:10.1016/j.lungcan.2007.10.011

Cited by 66 publications

(60 citation statements)

References 23 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, some of the studies used different methods, such as DNA from cell-free pleural fluid [26,27] or RNA sequencing [28,29], claiming that either they are more suitable for recognizing EGFR mutations, that they are complementary to classical DNA sequencing or involve lower costs [28,30,31]. This fact has a direct impact on the nonhomogenous methods to study EGFR mutations in pleural fluid, which therefore lead to variations in the rates of EGFR mutations reported.…”

Section: Epidermal Growth Factor Receptor Pathwaymentioning

confidence: 99%

Pleural Effusion in Lung Cancer: More Questions than Answers

Froudarakis

2012

Respiration

View full text Add to dashboard Cite

Lung cancer remains the most common fatal malignancy, despite more aggressive therapies. Few patients will survive 5 years, as up to 80% of the patients will present with advanced-stage disease at diagnosis. Chemotherapy offers little benefit in terms of median survival and disease-free survival in patients with advanced-stage non-small-cell lung carcinoma (NSCLC). In the last decade, the development of new targeted therapies based on the better understanding of different paths of carcinogenesis has given new hope to both physicians and patients. Metastatic pleural effusion from lung cancer has a particularly poor prognosis, and in NSCLC it is actually reclassified as stage IV disease. A possible explanation of this observation is differences in the genomics between primary tumors and metastasis, leading to possible different therapeutic approaches with novel molecular therapies in this patient population. The current review aims to summarize the actual situation of research in pleural disease due to lung carcinoma in relation to novel targeted therapies tested in this patient population.

show abstract

Section: Epidermal Growth Factor Receptor Pathwaymentioning

confidence: 99%

Pleural Effusion in Lung Cancer: More Questions than Answers

Froudarakis

2012

Respiration

View full text Add to dashboard Cite

show abstract

“…Sequencing is a straightforward method and is widely used [27][28][29]. However, the detection limit for direct sequencing is generally about 25-30% mutant alleles of total genomic DNA content [12,30]. Results of our mutant-enriched PCR sequencing method show it is more sensitive than the direct PCR sequencing, which is able to detect less than 10% mutant alleles of total genomic DNA content.…”

Section: Discussionmentioning

confidence: 90%

“…The major difficulty is that EGFR mutant cells are mixed by a large amount of wild cells derived from the site of tissue sampling. Currently, many of methods to overcome this obstacle have been reported, including PCR-RFLP analysis [12,13], co-amplification at lower denature-PCR [14], suspension array [15], ARMS PCR [16][17][18][19]. Among them, mutant-enriched PCR and ARMS PCR have been the major means for mutant alleles genotyping.…”

Section: Introductionmentioning

confidence: 99%

A novel method for detection of mutation in epidermal growth factor receptor

Zhao¹,

Zhao²,

Huang³

et al. 2011

Lung Cancer

View full text Add to dashboard Cite

“…Even if we could obtain homogeneous tumor samples, the somatic mutations were also heterogeneous [25]. Mutation content was often so little that the limit of detection of PCR sequencing couldn't reach.…”

Section: Discussionmentioning

confidence: 99%